CHICAGO, June 7 /PRNewswire-FirstCall/ -- The Female Health Company (Nasdaq: FHCO) today announced that on June 1, 2010, the U.S. Patent office issued patent number U.S. 7,726,316 B1 for its second generation product, the FC2 Female Condom. In addition to the newly issued U.S. patent, Spain, Greece and Turkey recently issued patents on the FC2 Female Condom.
In addition to the patents listed above, the Company also holds FC2 patents for Europe, Canada, Australia, South Africa and Japan. Patents are pending in various other countries.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in about 100 countries around the world. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., Europe, Canada, Australia, South Africa, Japan, Spain, Greece and Turkey and pending in various countries. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchanges Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from this currently anticipated.
For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com .
SOURCE The Female Health Company